The emerging roles and therapeutic potential of cyclindependent kinase 11 (CDK11) in human cancer

Oncotarget

Volumn 7, Issue 26, 2016, Pages 40846-40859

  Zhou, Yubing ^a,b   Shen, Jacson K ^b   Hornicek, Francis J ^b   Kan, Quancheng ^a   Duan, Zhenfeng ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cancer therapy; CDK11; CDKs inhibitor; Cell cycle; Therapeutic target

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 11; UNCLASSIFIED DRUG; CDK19 PROTEIN, HUMAN; PALBOCICLIB; PIPERAZINE DERIVATIVE; PROTEIN SERINE THREONINE KINASE; PYRIDINE DERIVATIVE;

ARTICLE; BREAST CANCER; CARCINOGENESIS; DISEASE ASSOCIATION; DNA SEQUENCE; DOWN REGULATION; ENZYME SPECIFICITY; GENE EXPRESSION REGULATION; HUMAN; LIPOSARCOMA; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE MYELOMA; NONHUMAN; OSTEOSARCOMA; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RNA PROCESSING; RNA TRANSCRIPTION; TRANSCRIPTION REGULATION; APOPTOSIS; BREAST TUMOR; CELL CYCLE; CELL PROLIFERATION; CHEMISTRY; GENE THERAPY; GENETIC EPIGENESIS; METABOLISM; NEOPLASM; PHOSPHORYLATION; RNA SPLICING; TREATMENT OUTCOME;

APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASES; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; HUMANS; LIPOSARCOMA; MULTIPLE MYELOMA; NEOPLASMS; OSTEOSARCOMA; PHOSPHORYLATION; PIPERAZINES; PROTEIN-SERINE-THREONINE KINASES; PYRIDINES; RNA SPLICING; TREATMENT OUTCOME;

EID: 84982950022     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8519     Document Type: Article

References (103)

1. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-674.
2. Du LL, DeFoe M, Ruzinova MB, Olsen JR and Wang-Gillam A. Perioperative Therapy for Surgically Resectable Pancreatic Adenocarcinoma. Hematol Oncol Clin N. 2015; 29:717-+.
3. Oseledchyk A and Zivanovic O. Intraoperative Hyperthermic Intraperitoneal Chemotherapy in Patients With Advanced Ovarian Cancer. Oncology (Williston Park). 2015; 29.
4. Stone JB and DeAngelis LM. Cancer-treatment-induced neurotoxicity-focus on newer treatments. Nature reviews Clinical oncology. 2016; 13:92-105. doi: 10.1038/ nrclinonc.2015.152.
5. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A and Griffin JD. Second generation inhibitors of BCRABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nature reviews Cancer. 2007; 7:345-356.
6. Gottesman MM, Fojo T and Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nature reviews Cancer. 2002; 2:48-58.
7. Rath SL and Senapati S. Molecular basis of differential selectivity of cyclobutyl-substituted imidazole inhibitors against CDKs: insights for rational drug design. PloS one. 2013; 8: e73836.
8. Lapenna S and Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009; 8:547-566.
9. Choi YJ and Anders L. Signaling through cyclin D-dependent kinases. Oncogene. 2014; 33:1890-1903.
10. Diaz-Moralli S, Tarrado-Castellarnau M, Miranda A and Cascante M. Targeting cell cycle regulation in cancer therapy. Pharmacol Therapeut. 2013; 138:255-271.
11. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol. 2006; 24:1770-1783.
12. Malinkova V, Vylicil J and Krystof V. Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009-2014). Expert opinion on therapeutic patents. 2015; 25:953-970.
13. Law ME, Corsino PE, Narayan S and Law BK. Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics. Molecular pharmacology. 2015; 88:846-852.
14. Sanchez-Martinez C, Gelbert LM, Lallena MJ and de Dios A. Cyclin dependent kinase (CDK) inhibitors as anticancer drugs. Bioorganic & medicinal chemistry letters. 2015; 25:3420-3435.
15. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, Shparyk Y, Thummala AR, Voytko NL, Fowst C, Huang X, Kim ST, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. The Lancet Oncology. 2015; 16:25-35.
16. Mangini NS, Wesolowski R, Ramaswamy B, Lustberg MB and Berger MJ. Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer. The Annals of pharmacotherapy. 2015; 49:1252-60. doi: 10.1177/1060028015602273.
17. Lu J. Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer. Journal of hematology & oncology. 2015; 8:98.
18. Turner NC, Ro J, Andre F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Huang Bartlett C, Zhang K, Giorgetti C, Randolph S, Koehler M and Cristofanilli M. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. The New England journal of medicine. 2015; 373:209-219.
19. Duan Z, Zhang J, Choy E, Harmon D, Liu X, Nielsen P, Mankin H, Gray NS and Hornicek FJ. Systematic kinome shRNA screening identifies CDK11 (PITSLRE) kinase expression is critical for osteosarcoma cell growth and proliferation. Clinical cancer research. 2012; 18:4580-4588.
20. Jia B, Choy E, Cote G, Harmon D, Ye S, Kan Q, Mankin H, Hornicek F and Duan Z. Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells. Cancer letters. 2014; 342:104-112.
21. Zhou Y, Han C, Li D, Yu Z, Li F, An Q, Bai H, Zhang X, Duan Z and Kan Q. Cyclin-dependent kinase 11(p110) (CDK11(p110)) is crucial for human breast cancer cell proliferation and growth. Scientific reports. 2015; 5:10433.
22. Tiedemann RE, Zhu YX, Schmidt J, Yin H, Shi CX, Que Q, Basu G, Azorsa D, Perkins LM, Braggio E, Fonseca R, Bergsagel PL, Mousses S and Stewart AK. Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6. Blood. 2010; 115:1594-1604.
23. Manning G, Whyte DB, Martinez R, Hunter T and Sudarsanam S. The protein kinase complement of the human genome. Science. 2002; 298:1912-1934.
24. Lim S and Kaldis P. Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development. 2013; 140:3079-3093.
25. Malumbres M, Harlow E, Hunt T, Hunter T, Lahti JM, Manning G, Morgan DO, Tsai LH and Wolgemuth DJ. Cyclin-dependent kinases: a family portrait. Nature cell biology. 2009; 11:1275-1276.
26. Malumbres M. Cyclin-dependent kinases. Genome biology. 2014; 15:122.
27. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. Journal of clinical oncology. 2006; 24:1770-1783.
28. Aleem E and Arceci RJ. Targeting cell cycle regulators in hematologic malignancies. Frontiers in cell and developmental biology. 2015; 3:16.
29. Cadoo KA, Gucalp A and Traina TA. Palbociclib: an evidence-based review of its potential in the treatment of breast cancer. Breast Cancer (Dove Med Press). 2014; 6:123-133.
30. Kim SH and Ryan TA. CDK5 serves as a major control point in neurotransmitter release. Neuron. 2010; 67:797-809.
31. Song WJ, Son MY, Lee HW, Seo H, Kim JH and Chung SH. Enhancement of BACE1 Activity by p25/Cdk5-Mediated Phosphorylation in Alzheimer's Disease. PloS one. 2015; 10: e0136950.
32. Su SC and Tsai LH. Cyclin-dependent kinases in brain development and disease. Annual review of cell and developmental biology. 2011; 27:465-491.
33. Duan C, Liu Y, Lu L, Cai R, Xue H, Mao X, Chen C, Qian R, Zhang D and Shen A. CDK14 Contributes to Reactive Gliosis via Interaction with Cyclin Y in Rat Model of Spinal Cord Injury. Journal of molecular neuroscience. 2015.
34. Park MH, Kim SY, Kim YJ and Chung YH. ALS2CR7 (CDK15) attenuates TRAIL induced apoptosis by inducing phosphorylation of survivin Thr34. Biochemical and biophysical research communications. 2014; 450:129-134.
35. Mikolcevic P, Sigl R, Rauch V, Hess MW, Pfaller K, Barisic M, Pelliniemi LJ, Boesl M and Geley S. Cyclin-dependent kinase 16/PCTAIRE kinase 1 is activated by cyclin Y and is essential for spermatogenesis. Molecular and cellular biology. 2012; 32:868-879.
36. Demirkan A, van Duijn CM, Ugocsai P, Isaacs A, Pramstaller PP, Liebisch G, Wilson JF, Johansson A, Rudan I, Aulchenko YS, Kirichenko AV, Janssens AC, Jansen RC, Gnewuch C, Domingues FS, Pattaro C, et al. Genome-wide association study identifies novel loci associated with circulating phospho- and sphingolipid concentrations. PLoS genetics. 2012; 8: e1002490.
37. Matsuda S, Kominato K, Koide-Yoshida S, Miyamoto K, Isshiki K, Tsuji A and Yuasa K. PCTAIRE kinase 3/cyclin-dependent kinase 18 is activated through association with cyclin A and/or phosphorylation by protein kinase A. The Journal of biological chemistry. 2014; 289:18387-18400.
38. Ohno S, Shibayama M, Sato M, Tokunaga A and Yoshida N. Polypyrimidine tract-binding protein regulates the cell cycle through IRES-dependent translation of CDK11(p58) in mouse embryonic stem cells. Cell Cycle. 2011; 10:3706-3713.
39. Meinhart A, Kamenski T, Hoeppner S, Baumli S and Cramer P. A structural perspective of CTD function. Genes & development. 2005; 19:1401-1415.
40. Trembley JH, Loyer P, Hu D, Li T, Grenet J, Lahti JM and Kidd VJ. Cyclin dependent kinase 11 in RNA transcription and splicing. Progress in nucleic acid research and molecular biology. 2004; 77:263-288.
41. Firestein R, Bass AJ, Kim SY, Dunn IF, Silver SJ, Guney I, Freed E, Ligon AH, Vena N, Ogino S, Chheda MG, Tamayo P, Finn S, Shrestha Y, Boehm JS, Jain S, et al. CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature. 2008; 455:547-551.
42. Zhao X, Feng D, Wang Q, Abdulla A, Xie XJ, Zhou J, Sun Y, Yang ES, Liu LP, Vaitheesvaran B, Bridges L, Kurland IJ, Strich R, Ni JQ, Wang C, Ericsson J, et al. Regulation of lipogenesis by cyclin-dependent kinase 8-mediated control of SREBP-1. The Journal of clinical investigation. 2012; 122:2417-2427.
43. Yu DS, Zhao R, Hsu EL, Cayer J, Ye F, Guo Y, Shyr Y and Cortez D. Cyclin-dependent kinase 9-cyclin K functions in the replication stress response. EMBO reports. 2010; 11:876-882.
44. Guen VJ, Gamble C, Flajolet M, Unger S, Thollet A, Ferandin Y, Superti-Furga A, Cohen PA, Meijer L and Colas P. CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110:19525-19530.
45. Trembley JH, Hu D, Hsu LC, Yeung CY, Slaughter C, Lahti JM and Kidd VJ. PITSLRE p110 protein kinases associate with transcription complexes and affect their activity. The Journal of biological chemistry. 2002; 277:2589-2596.
46. Cheng SW, Kuzyk MA, Moradian A, Ichu TA, Chang VC, Tien JF, Vollett SE, Griffith M, Marra MA and Morin GB. Interaction of cyclin-dependent kinase 12/CrkRS with cyclin K1 is required for the phosphorylation of the C-terminal domain of RNA polymerase II. Molecular and cellular biology. 2012; 32:4691-4704.
47. Liu X, Cheng C, Shao B, Wu X, Ji Y, Lu X and Shen A. LPS-stimulating astrocyte-conditioned medium causes neuronal apoptosis via increasing CDK11(p58) expression in PC12 cells through downregulating AKT pathway. Cellular and molecular neurobiology. 2013; 33:779-787.
48. Mukhopadhyay A, Kramer JM, Merkx G, Lugtenberg D, Smeets DF, Oortveld MA, Blokland EA, Agrawal J, Schenck A, van Bokhoven H, Huys E, Schoenmakers EF, van Kessel AG, van Nouhuys CE and Cremers FP. CDK19 is disrupted in a female patient with bilateral congenital retinal folds, microcephaly and mild mental retardation. Human genetics. 2010; 128:281-291.
49. Feng H, Cheng AS, Tsang DP, Li MS, Go MY, Cheung YS, Zhao GJ, Ng SS, Lin MC, Yu J, Lai PB, To KF and Sung JJ. Cell cycle-related kinase is a direct androgen receptor-regulated gene that drives beta-catenin/T cell factor-dependent hepatocarcinogenesis. The Journal of clinical investigation. 2011; 121:3159-3175.
50. Canavese M, Santo L and Raje N. Cyclin dependent kinases in cancer: potential for therapeutic intervention. Cancer biology & therapy. 2012; 13:451-457.
51. Chen TJ, Lee SW, Lin LC, Lin CY, Chang KY and Li CF. Cyclin-dependent kinase 4 overexpression is mostly independent of gene amplification and constitutes an independent prognosticator for nasopharyngeal carcinoma. Tumour biology. 2014; 35:7209-7216.
52. Diaz-Moralli S, Tarrado-Castellarnau M, Miranda A and Cascante M. Targeting cell cycle regulation in cancer therapy. Pharmacology & therapeutics. 2013; 138:255-271.
53. Park S, Lee J, Do IG, Jang J, Rho K, Ahn S, Maruja L, Kim SJ, Kim KM, Mao M, Oh E, Kim YJ, Kim J and Choi YL. Aberrant CDK4 amplification in refractory rhabdomyosarcoma as identified by genomic profiling. Scientific reports. 2014; 4:3623.
54. Lapenna S and Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nature reviews Drug discovery. 2009; 8:547-566.
55. Romano G and Giordano A. Role of the cyclin-dependent kinase 9-related pathway in mammalian gene expression and human diseases. Cell Cycle. 2008; 7:3664-3668.
56. Loyer P, Trembley JH, Katona R, Kidd VJ and Lahti JM. Role of CDK/cyclin complexes in transcription and RNA splicing. Cellular signalling. 2005; 17:1033-1051.
57. Wilkinson S, Croft DR, O'Prey J, Meedendorp A, O'Prey M, Dufes C and Ryan KM. The cyclin-dependent kinase PITSLRE/CDK11 is required for successful autophagy. Autophagy. 2011; 7:1295-1301.
58. Bajic VP, Su B, Lee HG, Kudo W, Siedlak SL, Zivkovic L, Spremo-Potparevic B, Djelic N, Milicevic Z, Singh AK, Fahmy LM, Wang X, Smith MA and Zhu X. Mislocalization of CDK11/PITSLRE, a regulator of the G2/M phase of the cell cycle, in Alzheimer disease. Cellular & molecular biology letters. 2011; 16:359-372.
59. Gururajan R, Lahti JM, Grenet J, Easton J, Gruber I, Ambros PF and Kidd VJ. Duplication of a genomic region containing the Cdc2L1-2 and MMP21-22 genes on human chromosome 1p36.3 and their linkage to D1Z2. Genome research. 1998; 8:929-939.
60. Hu D, Mayeda A, Trembley JH, Lahti JM and Kidd VJ. CDK11 complexes promote pre-mRNA splicing. The Journal of biological chemistry. 2003; 278:8623-8629.
61. Loyer P, Trembley JH, Grenet JA, Busson A, Corlu A, Zhao W, Kocak M, Kidd VJ and Lahti JM. Characterization of cyclin L1 and L2 interactions with CDK11 and splicing factors: influence of cyclin L isoforms on splice site selection. The Journal of biological chemistry. 2008; 283:7721-7732.
62. Lahti JM, Xiang J, Heath LS, Campana D and Kidd VJ. PITSLRE protein kinase activity is associated with apoptosis. Molecular and cellular biology. 1995; 15:1-11.
63. Beyaert R, Kidd VJ, Cornelis S, Van de Craen M, Denecker G, Lahti JM, Gururajan R, Vandenabeele P and Fiers W. Cleavage of PITSLRE kinases by ICE/CASP-1 and CPP32/ CASP-3 during apoptosis induced by tumor necrosis factor. The Journal of biological chemistry. 1997; 272:11694-11697.
64. Ariza ME, Broome-Powell M, Lahti JM, Kidd VJ and Nelson MA. Fas-induced apoptosis in human malignant melanoma cell lines is associated with the activation of the p34(cdc2)-related PITSLRE protein kinases. The Journal of biological chemistry. 1999; 274:28505-28513.
65. Loyer P, Trembley JH, Lahti JM and Kidd VJ. The RNP protein, RNPS1, associates with specific isoforms of the p34cdc2-related PITSLRE protein kinase in vivo. Journal of cell science. 1998; 111:1495-1506.
66. Cornelis S, Bruynooghe Y, Denecker G, Van Huffel S, Tinton S and Beyaert R. Identification and characterization of a novel cell cycle-regulated internal ribosome entry site. Molecular cell. 2000; 5:597-605.
67. Choi HH, Choi HK, Jung SY, Hyle J, Kim BJ, Yoon K, Cho EJ, Youn HD, Lahti JM, Qin J and Kim ST. CHK2 kinase promotes pre-mRNA splicing via phosphorylating CDK11(p110). Oncogene. 2014; 33:108-115.
68. Loyer P, Busson A, Trembley JH, Hyle J, Grenet J, Zhao W, Ribault C, Montier T, Kidd VJ and Lahti JM. The RNA binding motif protein 15B (RBM15B/OTT3) is a functional competitor of serine-arginine (SR) proteins and antagonizes the positive effect of the CDK11p110-cyclin L2alpha complex on splicing. The Journal of biological chemistry. 2011; 286:147-159.
69. Drogat J, Migeot V, Mommaerts E, Mullier C, Dieu M, van Bakel H and Hermand D. Cdk11-cyclinL controls the assembly of the RNA polymerase II mediator complex. Cell reports. 2012; 2:1068-1076.
70. Franck N, Montembault E, Rome P, Pascal A, Cremet JY and Giet R. CDK11(p58) is required for centriole duplication and Plk4 recruitment to mitotic centrosomes. PloS one. 2011; 6: e14600.
71. Petretti C, Savoian M, Montembault E, Glover DM, Prigent C and Giet R. The PITSLRE/CDK11p58 protein kinase promotes centrosome maturation and bipolar spindle formation. EMBO reports. 2006; 7:418-424.
72. Hu D, Valentine M, Kidd VJ and Lahti JM. CDK11(p58) is required for the maintenance of sister chromatid cohesion. Journal of cell science. 2007; 120:2424-2434.
73. Li T, Inoue A, Lahti JM and Kidd VJ. Failure to proliferate and mitotic arrest of CDK11(p110/p58)-null mutant mice at the blastocyst stage of embryonic cell development. Molecular and cellular biology. 2004; 24:3188-3197.
74. Yokoyama H, Gruss OJ, Rybina S, Caudron M, Schelder M, Wilm M, Mattaj IW and Karsenti E. Cdk11 is a RanGTP-dependent microtubule stabilization factor that regulates spindle assembly rate. The Journal of cell biology. 2008; 180:867-875.
75. Barna M, Pusic A, Zollo O, Costa M, Kondrashov N, Rego E, Rao PH and Ruggero D. Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency. Nature. 2008; 456:971-975.
76. Wilker EW, van Vugt MA, Artim SA, Huang PH, Petersen CP, Reinhardt HC, Feng Y, Sharp PA, Sonenberg N, White FM and Yaffe MB. 14-3-3sigma controls mitotic translation to facilitate cytokinesis. Nature. 2007; 446:329-332.
77. Rakkaa T, Escude C, Giet R, Magnaghi-Jaulin L and Jaulin C. CDK11(p58) kinase activity is required to protect sister chromatid cohesion at centromeres in mitosis. Chromosome research. 2014; 22:267-276.
78. Zhang S, Cai M, Xu S, Chen S, Chen X, Chen C and Gu J. Interaction of p58(PITSLRE), a G2/M-specific protein kinase, with cyclin D3. The Journal of biological chemistry. 2002; 277:35314-35322.
79. Shi J, Feng Y, Goulet AC, Vaillancourt RR, Sachs NA, Hershey JW and Nelson MA. The p34cdc2-related cyclin-dependent kinase 11 interacts with the p47 subunit of eukaryotic initiation factor 3 during apoptosis. The Journal of biological chemistry. 2003; 278:5062-5071.
80. Mikolajczyk M, Shi J, Vaillancourt RR, Sachs NA and Nelson M. The cyclin-dependent kinase 11(p46) isoform interacts with RanBPM. Biochemical and biophysical research communications. 2003; 310:14-18.
81. Trembley JH, Hu D, Slaughter CA, Lahti JM and Kidd VJ. Casein kinase 2 interacts with cyclin-dependent kinase 11 (CDK11) in vivo and phosphorylates both the RNA polymerase II carboxyl-terminal domain and CDK11 in vitro. The Journal of biological chemistry. 2003; 278:2265-2270.
82. Nybakken K, Vokes SA, Lin TY, McMahon AP and Perrimon N. A genome-wide RNA interference screen in Drosophila melanogaster cells for new components of the Hh signaling pathway. Nature genetics. 2005; 37:1323-1332.
83. Evangelista M, Lim TY, Lee J, Parker L, Ashique A, Peterson AS, Ye W, Davis DP and de Sauvage FJ. Kinome siRNA screen identifies regulators of ciliogenesis and hedgehog signal transduction. Science signaling. 2008; 1: ra7.
84. Naik S, Dothager RS, Marasa J, Lewis CL and Piwnica-Worms D. Vascular Endothelial Growth Factor Receptor-1 Is Synthetic Lethal to Aberrant beta-Catenin Activation in Colon Cancer. Clinical cancer research. 2009; 15:7529-7537.
85. Jiang J and Hui CC. Hedgehog signaling in development and cancer. Developmental cell. 2008; 15:801-812.
86. Petrova R and Joyner AL. Roles for Hedgehog signaling in adult organ homeostasis and repair. Development. 2014; 141:3445-3457.
87. MacDonald BT, Tamai K and He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Developmental cell. 2009; 17:9-26.
88. Kahle A, Feng Y and M AN. Isolation and characterization of the human Cdc2L1 gene promoter. Gene. 2005; 344:53-60.
89. Feng Y, Goulet AC and Nelson MA. Identification and characterization of the human Cdc212 gene promoter. Gene. 2004; 330:75-84.
90. Sachs NA and Vaillancourt RR. Cyclin-dependent kinase 11(p110) activity in the absence of CK2. Biochimica et biophysica acta. 2003; 1624:98-108.
91. Kugler MC, Joyner AL, Loomis CA and Munger JS. Sonic hedgehog signaling in the lung. From development to disease. American journal of respiratory cell and molecular biology. 2015; 52:1-13.
92. Briscoe J and Therond PP. The mechanisms of Hedgehog signalling and its roles in development and disease. Nature reviews Molecular cell biology. 2013; 14:416-429.
93. Mikolajczyk M and Nelson MA. Regulation of stability of cyclin-dependent kinase CDK11p110 and a caspase-processed form, CDK11p46, by Hsp90. The Biochemical journal. 2004; 384:461-467.
94. Feng Y, Qi W, Martinez J and Nelson MA. The cyclin-dependent kinase 11 interacts with 14-3-3 proteins. Biochemical and biophysical research communications. 2005; 331:1503-1509.
95. Pierre F, Chua PC, O'Brien SE, Siddiqui-Jain A, Bourbon P, Haddach M, Michaux J, Nagasawa J, Schwaebe MK, Stefan E, Vialettes A, Whitten JP, Chen TK, Darjania L, Stansfield R, Bliesath J, et al. Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer. Molecular and cellular biochemistry. 2011; 356:37-43.
96. Seto T, Esaki T, Hirai F, Arita S, Nosaki K, Makiyama A, Kometani T, Fujimoto C, Hamatake M, Takeoka H, Agbo F and Shi X. Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours. Cancer chemotherapy and pharmacology. 2013; 72:619-627.
97. Kren BT, Unger GM, Abedin MJ, Vogel RI, Henzler CM, Ahmed K and Trembley JH. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy. Breast cancer research. 2015; 17:19.
98. Tiedemann RE, Zhu YX, Schmidt J, Shi CX, Sereduk C, Yin H, Mousses S and Stewart AK. Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome. Cancer research. 2012; 72:757-768.
99. Feng Y, Sassi S, Shen JK, Yang X, Gao Y, Osaka E, Zhang J, Yang S, Yang C, Mankin HJ, Hornicek FJ and Duan Z. Targeting CDK11 in osteosarcoma cells using the CRISPR-Cas9 system. Journal of orthopaedic research. 2015; 33:199-207.
100. Xiang J, Lahti JM, Grenet J, Easton J and Kidd VJ. Molecular cloning and expression of alternatively spliced PITSLRE protein kinase isoforms. The Journal of biological chemistry. 1994; 269:15786-15794.
101. Housden BE, Valvezan AJ, Kelley C, Sopko R, Hu Y, Roesel C, Lin S, Buckner M, Tao R, Yilmazel B, Mohr SE, Manning BD and Perrimon N. Identification of potential drug targets for tuberous sclerosis complex by synthetic screens combining CRISPR-based knockouts with RNAi. Science signaling. 2015; 8: rs9.
102. Pak V, Eifler TT, Jager S, Krogan NJ, Fujinaga K and Peterlin BM. CDK11 in TREX/THOC Regulates HIV mRNA 3' End Processing. Cell host & microbe. 2015; 18:560-570.
103. Cary DC, Fujinaga K and Peterlin BM. Molecular mechanisms of HIV latency. The Journal of clinical investigation. 2016:1-7.